Quartuccio, L., Sonaglia, A., Pecori, D., Peghin, M., Fabris, M., Tascini, C., & De Vita, S. (2020). Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6. J Med Virol.

Quartuccio, Luca, Arianna Sonaglia, Davide Pecori, Maddalena Peghin, Martina Fabris, Carlo Tascini, e Salvatore De Vita. "Higher Levels of IL‐6 Early After Tocilizumab Distinguish Survivors From Nonsurvivors in COVID‐19 Pneumonia: A Possible Indication for Deeper Targeting of IL‐6." J Med Virol 2020.

Quartuccio, Luca, et al. "Higher Levels of IL‐6 Early After Tocilizumab Distinguish Survivors From Nonsurvivors in COVID‐19 Pneumonia: A Possible Indication for Deeper Targeting of IL‐6." J Med Virol 2020.